

# Mohini S Ghatge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10232183/publications.pdf>

Version: 2024-02-01

19  
papers

443  
citations

933447

10  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemoglobin: Structure, Function and Allostery. <i>Sub-Cellular Biochemistry</i> , 2020, 94, 345-382.	2.4	106
2	Hemoglobinâ€“ligand binding: Understanding Hb function and allostery on atomic level. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 797-809.	2.3	76
3	Pyridoxal 5â€“Phosphate Is a Slow Tight Binding Inhibitor of E. coli Pyridoxal Kinase. <i>PLoS ONE</i> , 2012, 7, e41680.	2.5	48
4	Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2011, 67, 920-928.	2.5	41
5	Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation. <i>Journal of Structural Biology</i> , 2016, 194, 446-450.	2.8	30
6	Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2530-2538.	3.0	26
7	Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies. <i>Biochimie</i> , 2021, 183, 18-29.	2.6	16
8	Inactive mutants of human pyridoxine 5â€“phosphate oxidase: a possible role for a noncatalytic pyridoxal 5â€“phosphate tight binding site. <i>FEBS Open Bio</i> , 2016, 6, 398-408.	2.3	15
9	Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation. <i>Acta Crystallographica Section D: Structural Biology</i> , 2018, 74, 956-964.	2.3	15
10	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. <i>Scientific Reports</i> , 2020, 10, 20277.	3.3	14
11	The plmS 2 -Encoded Cytochrome P450 Monooxygenase Mediates Hydroxylation of Phoslactomycin B in <i>Streptomyces</i> sp. Strain HK803. <i>Journal of Bacteriology</i> , 2005, 187, 7970-7976.	2.2	13
12	Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobinâ€“NO Biochemistry. <i>Biochemistry</i> , 2015, 54, 7178-7192.	2.5	9
13	Molecular basis of E. coli l-threonine aldolase catalytic inactivation at low pH. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 278-283.	2.3	7
14	Exploration of Structureâ€“Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14724-14739.	6.4	7
15	An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. <i>Biomolecules</i> , 2020, 10, 1508.	4.0	6
16	Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin. <i>Molecules</i> , 2016, 21, 1057.	3.8	4
17	Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 472-482.	2.3	4
18	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. <i>Biomolecules</i> , 2022, 12, 696.	4.0	4

#	ARTICLE	IF	CITATIONS
19	Vzhe-039, a Novel Structurally-Enhanced Allosteric Hemoglobin Effector Inhibits Sickling of SS Erythrocytes In Vitro, and Exhibits Improved Pharmacologic Properties In Vivo. <i>Blood</i> , 2016, 128, 3645-3645.	1.4	2